Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Simris Group

0,09 SEK

-0,93 %

Mindre end 1K følgere

SIMRIS B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
-0,93 %
-18,67 %
-29,71 %
-34,31 %
+12,07 %
+2,64 %
-70,96 %
-87,12 %
-98,47 %

Simris Group is a biotechnology company. The company is focused on research and development of bioactive substances from cultured microalgae, for applications in nutrition, cosmeceuticals and pharmaceuticals. The company's technology also replaces unsustainable raw materials from endangered species and sensitive marine ecosystems. Simris Group was founded in 2011 and is headquartered in Hammenhög.

Læs mere
Markedsværdi
53,39 mio. SEK
Aktieomsætning
10,53 t SEK
Omsætning
2,89 mio.
EBIT %
-1.201,04 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
25.2
2026

Årsrapport '25

Alle
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Selskabsmeddelelse28.11.2025, 15.51

Simris Group enters into bridge loan agreement

Simris Group
Selskabsmeddelelse12.11.2025, 07.00

SIMRIS GROUP INTERIM REPORT JANUARY-SEPTEMBER 2025

Simris Group
Selskabsmeddelelse10.11.2025, 07.30

Simris Group announces leadership transition - Daniel Kubitza appointed interim CEO

Simris Group

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse5.11.2025, 12.00

Simris Group AB Announces Positive Results from Ongoing Antibody-Drug Conjugate (ADC) Study with Nuvisan

Simris Group
Selskabsmeddelelse6.10.2025, 07.30

Update Regarding In-Vitro Evaluation of Novel Advance Microcystin Payloads

Simris Group
Pressemeddelelse12.9.2025, 08.00

Simris Biologics awarded €200K in non-dilutive funding for R&D programme to further develop microcystin payloads for Antibody Drug Conjugates (ADCs)

Simris Group
Selskabsmeddelelse13.8.2025, 06.00

SIMRIS GROUP INTERIM REPORT JANUARY-JUNE 2025

Simris Group
Selskabsmeddelelse27.7.2025, 19.57

Simris Group AB (publ) resolves on a directed issue of convertible debentures of EUR 678,000 and amends existing loan facilities

Simris Group
Selskabsmeddelelse12.7.2025, 04.38

Partner Company Decides Not to Proceed with Simris Group ADC Proposed Collaboration Following Strategic Review

Simris Group
Pressemeddelelse5.6.2025, 07.15

Simris Biologics Signs Agreement with Nuvisan for In-Vivo Evaluation of Novel Microcystin Payloads

Simris Group
Selskabsmeddelelse2.6.2025, 06.55

Simris Group AB Signs Non-Binding Concept Sheet for Potential Antibody-Drug Conjugate Collaboration

Simris Group
Selskabsmeddelelse28.5.2025, 15.10

Bulletin from Simris Group AB’s annual general meeting

Simris Group
Selskabsmeddelelse14.5.2025, 06.00

SIMRIS GROUP INTERIM REPORT JANUARY-MARCH 2025

Simris Group
Selskabsmeddelelse25.4.2025, 13.00

Notice of the Annual General Meeting of Simris Group AB (publ)

Simris Group
Selskabsmeddelelse16.4.2025, 16.05

Simris Group enters into bridge loan agreement, extends loan agreements with investors and intends to propose that the annual general meeting resolves to extend loan agreements with management

Simris Group
Selskabsmeddelelse16.4.2025, 13.00

SIMRIS GROUP PUBLISHES ITS ANNUAL REPORT FOR 2024

Simris Group
Pressemeddelelse25.3.2025, 07.00

Refined Microcystin Payloads Show Promising In-Vitro Efficacy, Paving Way for Next-Generation Variants

Simris Group
Selskabsmeddelelse26.2.2025, 07.00

SIMRIS GROUP YEAR-END REPORT JANUARY-DECEMBER 2024

Simris Group
Selskabsmeddelelse20.1.2025, 13.18

Bulletin from Simris Group AB’s Extraordinary General Meeting

Simris Group
Selskabsmeddelelse23.12.2024, 10.07

Notice of Extraordinary General Meeting of Simris Group AB (publ)

Simris Group
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.